Growth of 40% per annum continues for AFT Pharmaceuticals in the Australasian market (Australia and NZ) with sales for this year due to break $22 million per annum.
AFT Group Sales Growth continues at +40%
Similar articles
Maxigesic® IV licensed in eight new European markets
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed an exclusive Maxigesic® IV licensing agreement for eight new European markets.
Read more
AFT Pharmaceuticals’ achieves first registration of it’s patented painkiller Maxigesic IV® in the pivotal Australian market
AFT Pharmaceuticals (AFT’) today announces it has successfully registered the intravenous form of its successful Maxigesic’ pain relief medication with Australia’s Therapeutic Goods Administration (TGA).
Read more
AFT Pharmaceuticals’ completes new deals for Maxigesic® in Mexico, Switzerland and Cyprus
AFT Pharmaceuticals’ completes another 3 deals: Painkiller Maxigesic IV® is
now licensed in Mexico together with Maxigesic® tablets in Switzerland and
Cyprus
Read more